February proved to be a slow month for medtech M&A, with Medtech Insight recording only nine deals for the month. This was significantly down from the 17 deals in January and the 12 recorded in the same period last year. (See Figure 1.) However, there was a buzz of activity in the oncology and cardiovascular space (see Figure 2), with Varian striking two more deals to expand its radiation oncology business.
M&A Analysis: February, Onco And Cardio Deals Invade Frosty Month
Medtech Insight recorded nine newly announced deals in February, a decline from the 17 deals recorded in January 2017 and the 12 noted in the same period last year. Nevertheless, it proved to be a busy month in the oncology and cardiovascular space, with radiotherapy specialist Varian racking up two deals in the same month to expand its cancer portfolio.
More from Business
More from Medtech Insight
• By
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
• By
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
• By
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.